1. Home
  2. LTRX vs CRDF Comparison

LTRX vs CRDF Comparison

Compare LTRX & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantronix Inc.

LTRX

Lantronix Inc.

HOLD

Current Price

$6.89

Market Cap

225.9M

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$2.90

Market Cap

187.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTRX
CRDF
Founded
1989
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Communications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
225.9M
187.9M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
LTRX
CRDF
Price
$6.89
$2.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$6.17
$10.83
AVG Volume (30 Days)
584.8K
990.1K
Earning Date
02-05-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$118,294,000.00
$501,000.00
Revenue This Year
$4.59
N/A
Revenue Next Year
$12.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.91
$1.90
52 Week High
$6.96
$4.99

Technical Indicators

Market Signals
Indicator
LTRX
CRDF
Relative Strength Index (RSI) 72.98 55.24
Support Level $5.94 $2.72
Resistance Level $6.63 $3.31
Average True Range (ATR) 0.38 0.20
MACD 0.07 -0.04
Stochastic Oscillator 98.07 41.40

Price Performance

Historical Comparison
LTRX
CRDF

About LTRX Lantronix Inc.

Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Share on Social Networks: